Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry

Berg, Jenny; Lindgren, Peter; Mejhert, Märit; Edner, Magnus; Dahlström, Ulf; Kahan, Thomas

doi:10.1016/j.jval.2015.02.003

Cited by 26 publications

(28 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The generic EQ‐5D domain scores and the VAS, which reflect patients' own assessment of their global health, while less specific to the aspects of health important to patients with HF, are also in line with the KCCQ results and extend assessment to the potential impact of vericiguat on broader aspects of HRQoL. Summary score improvements for the 5 and 10 mg arms were at a meaningful level (defined as 0.04 and 5 points for the US index score and the VAS, respectively) …”

Section: Discussionsupporting

confidence: 61%

“…The results of the exploratory patient‐reported endpoints in the SOCRATES‐PRESERVED trial, in the absence of changes in the primary endpoints, NT‐proBNP and LAV, generate the hypothesis of a potential clinically relevant improvement in patient health status in the higher dose arms of vericiguat. In key domains of the KCCQ and EQ‐5D, mean changes relative to placebo were above previously defined levels of MCID . At the level of individual patients, the responder analyses suggest as few as three to five patients need to be treated with the higher doses of vericiguat for one to feel moderately or substantially better.…”

Section: Discussionmentioning

confidence: 81%

See 1 more Smart Citation

Patient‐reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES‐PRESERVED) study

Filippatos

Maggioni

Lam

et al. 2017

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 81%

Patient‐reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES‐PRESERVED) study

Filippatos

Maggioni

Lam

et al. 2017

European J of Heart Fail

View full text Add to dashboard Cite

show abstract

“…However, the assumption of an annual decline in EQ-5D of 0.008 appears consistent with data from other studies; 1-year longitudinal data presented by Berg et al in patients with chronic HF suggests an annual decrease in EQ-5D of 0.006. 29 …”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction

McMurray

Trueman²,

Hancock³

et al. 2017

Heart

View full text Add to dashboard Cite

ObjectiveChronic heart failure with reduced ejection fraction (HF-REF) represents a major public health issue and is associated with considerable morbidity and mortality. We evaluated the cost-effectiveness of sacubitril/valsartan (formerly LCZ696) compared with an ACE inhibitor (ACEI) (enalapril) in the treatment of HF-REF from the perspective of healthcare providers in the UK, Denmark and Colombia.MethodsA cost-utility analysis was performed based on data from a multinational, Phase III randomised controlled trial. A decision-analytic model was developed based on a series of regression models, which extrapolated health-related quality of life, hospitalisation rates and survival over a lifetime horizon. The primary outcome was the incremental cost-effectiveness ratio (ICER).ResultsIn the UK, the cost per quality-adjusted life-year (QALY) gained for sacubitril/valsartan (using cardiovascular mortality) was £17 100 (€20 400) versus enalapril. In Denmark, the ICER for sacubitril/valsartan was Kr 174 000 (€22 600). In Colombia, the ICER was COP$39.5 million (€11 200) per QALY gained. Deterministic sensitivity analysis showed that results were most sensitive to the extrapolation of mortality, duration of treatment effect and time horizon, but were robust to other structural changes, with most scenarios associated with ICERs below the willingness-to-pay threshold for all three country settings. Probabilistic sensitivity analysis suggested the probability that sacubitril/valsartan was cost-effective at conventional willingness-to-pay thresholds was 68%–94% in the UK, 84% in Denmark and 95% in Colombia.ConclusionsOur analysis suggests that, in all three countries, sacubitril/valsartan is likely to be cost-effective compared with an ACEI (the current standard of care) in patients with HF-REF.

show abstract

“…Meanwhile, higher EQ-5D US index scores were achieved after using of vericigaut and riociguat, which reflected the improved health of patients with HF. [ 25 , 26 ] Moreover, SOCRATES-PRESERVED trial reported higher doses of vericigaut (5 and 10 mg) mainly played the import role in increasing scores. But dose-dependent effects are not observed in the treatment of riociguat.…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure

Zheng

Xiong

et al. 2018

Medicine

View full text Add to dashboard Cite

Background:Several randomized controlled trials (RCTs) have been investigated the benefits of soluble guanylate cyclase (sGC) stimulators in the treatment of heart failure, but a comprehensive evaluation is lacking. We performed a meta-analysis to evaluate the efficacy and safety of oral sGC stimulators (vericiguat and riociguat) in patients with heart failure.Methods:Studies were searched and screened in PubMed, Embase, and Cochrane Library. Eligible RCTs were included that reported mortality, the change of EuroQol Group 5-Dmensional Self-report Questionnaire (EQ-5D) US index, N-terminal pro-B-type natriuretic peptide (NT-proBNP), or serious adverse events (SAEs). Relative risk or weight mean difference (WMD) was estimated using fixed effect model or random effect model. Analysis of sensitivity and publication bias was conducted.Results:Five trials with a total of 1200 patients were included. sGC stimulators had no impact on the mortality (1.25; 95% confidence interval 0.50–3.11) and significantly improved EQ-5D US index (0.04; 95% confidence interval 0.020–0.05). Furthermore, in comparison with control group, NT-proBNP was statistically decreased in riociguat group (−0.78; 95% confidence interval −1.01 to −0.47), but not in vericiguat group (0.04, 95% confidence interval −0.18 to 0.25). There were not obverse differences in SAEs between sGC stimulators and control groups (0.90; 95% confidence interval 0.72–1.12).Conclusion:Our meta-analysis suggests that sGC stimulators could improve the quality of life in patients with heart failure with good tolerance and safety, but their long-term benefits need to be observed in the future. sGC stimulators are likely to be promising add-on strategies for the treatment of heart failure.

show abstract

Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry

Abstract: Utilities in CHF and their change over time are influenced by diverse demographic and clinical factors. Our findings can be used to target clinical interventions and for economic evaluations of new therapies.

Cited by 26 publications

References 37 publications

Patient‐reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES‐PRESERVED) study

Patient‐reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES‐PRESERVED) study

Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction

The efficacy and safety of soluble guanylate cyclase stimulators in patients with heart failure

Contact Info

Product

Resources

About